PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsInterferon beta
Interferon beta
Avonex, Rebif (interferon beta) is a protein pharmaceutical. Interferon beta was first approved as Avonex on 1997-03-13. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against interleukin-6 receptor subunit alpha and interleukin-6. In addition, it is known to target interferon alpha/beta receptor 1.
Download report
Favorite
COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
avonexBiologic Licensing Application2016-03-31
avonex avonex avonex penBiologic Licensing Application2020-12-16
avonex avonex penBiologic Licensing Application2023-07-31
betaseronBiologic Licensing Application2023-07-28
rebifBiologic Licensing Application2010-01-14
rebif rebif rebidoseBiologic Licensing Application2023-08-04
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AB: Interferons
— L03AB02: Interferon beta natural
— L03AB07: Interferon beta-1a
— L03AB08: Interferon beta-1b
HCPCS
Code
Description
J1826
Injection, interferon beta-1a, 30 mcg
J1830
Injection, interferon beta-1b, 0.25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Q3027
Injection, interferon beta-1a, 1 mcg for intramuscular use
Q3028
Injection, interferon beta-1a, 1 mcg for subcutaneous use
Clinical
Clinical Trials
383 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G3514446353123291
SclerosisD012598——7396249108260
Relapsing-remitting multiple sclerosisD020529EFO_0003929—523353543140
Covid-19D000086382———962522
SyndromeD013577——312128
Hepatitis cD006526—B19.2——22—4
Chronic hepatitis cD019698EFO_0004220B18.2——22—4
NeuritisD009443———212—4
Optic neuritisD009902EFO_0007405H46—212—4
HepatitisD006505HP_0012115K75.9——21—3
Show 11 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronavirus infectionsD018352EFO_0007224B34.2—35—28
Chronic progressive multiple sclerosisD020528EFO_0003840—1—1—35
Respiratory distress syndromeD012128EFO_1000637J80112—14
Hiv infectionsD015658EFO_0000764B201—1—13
PneumoniaD011014EFO_0003106———1—12
Severe acute respiratory syndromeD045169EFO_0000694J12.81——2——2
CoronavirusD017934————1—12
Acute lung injuryD055371EFO_0004610—111——2
Newborn respiratory distress syndromeD012127—P22111——2
DermatomyositisD003882EFO_0000398M33—11——2
Show 10 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.065———8
NeoplasmsD009369—C8061———6
InfectionsD007239EFO_0000544——2——35
MelanomaD008545——33———5
AsthmaD001249EFO_0000270J4512——14
RecurrenceD012008——31——14
Non-hodgkin lymphomaD008228—C85.941———4
LymphomaD008223—C85.941———4
Merkel cell carcinomaD015266EFO_1001471C4A32———3
LeukemiaD007938—C9531———3
Show 39 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———11————11
MycosesD009181—B35-B492————2
Myelodysplastic syndromesD009190—D462————2
Myeloid leukemia acuteD015470—C92.02————2
Multiple myelomaD009101—C90.02————2
T-cell lymphomaD016399——2————2
Large-cell lymphoma anaplasticD017728—C84.62————2
T-cell lymphoma peripheralD016411——2————2
Mycosis fungoidesD009182—C84.02————2
Myeloid leukemiaD007951—C922————2
Show 44 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Communicable diseasesD003141——————22
LeukoencephalopathiesD056784HP_0002352—————22
Progressive multifocal leukoencephalopathyD007968EFO_0007455A81.2————22
AtrophyD001284——————22
HemorrhageD006470MP_0001914R58————11
Heart failureD006333HP_0001635I50————11
HypertensionD006973EFO_0000537I10————11
MenorrhagiaD008595EFO_0003945N92.0————11
Hemophilia aD006467EFO_0007267D66————11
PainD010146EFO_0003843R52————11
Show 46 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameInterferon beta
INNinterferon beta
Description
The type-I interferons (IFN) are cytokines which play essential roles in inflammation, immunoregulation, tumor cells recognition, and T-cell responses. In the human genome, a cluster of thirteen functional IFN genes is located at the 9p21.3 cytoband over approximately 400 kb including coding genes for IFNα (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17 and IFNA21), IFNω (IFNW1), IFNɛ (IFNE), IFNк (IFNK) and IFNβ (IFNB1), plus 11 IFN pseudogenes.
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>4CNI:A,H|OLOKIZUMAB HEAVY CHAIN, FAB PORTION EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNS LYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES >4CNI:B,L|OLOKIZUMAB LIGHT CHAIN, FAB PORTION DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCLQHNSAPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB1AU1, 1IFA, 1P9M, 1WU3, 2EZD, 2EZE, 2EZF, 2EZG, 2M1X, 2M63, 2MS7, 2MS8, 2VGQ, 3J6C, 3J6J, 3WCY, 4BSX, 4C0M, 4CNI, 4GHU, 4J4L, 4NI7, 4NI9, 4O9H, 4P4H, 4Z8M, 4ZS7, 5FUC, 7NXZ, 8D82
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108510
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDV9GU1EM8SF (ChemIDplus, GSRS)
Target
Agency Approved
IL6R
IL6R
IL6
IL6
Organism
Homo sapiens
Gene name
IL6R
Gene synonyms
NCBI Gene ID
3570
Protein name
interleukin-6 receptor subunit alpha
Protein synonyms
CD126, CD126 antigen, gp80, IL-6 receptor subunit alpha, IL-6R 1, Membrane glycoprotein 80
Uniprot ID
Q5VZ23
Mouse ortholog
Il6ra (16194)
interleukin-6 receptor subunit alpha (P22272)
Alternate
IFNAR1
IFNAR1
Organism
Homo sapiens
Gene name
IFNAR1
Gene synonyms
IFNAR
NCBI Gene ID
3454
Protein name
interferon alpha/beta receptor 1
Protein synonyms
alpha-type antiviral protein, beta-type antiviral protein, CRF2-1, Cytokine receptor class-II member 1, Cytokine receptor family 2 member 1, IFN-alpha/beta receptor 1, IFN-R-1, IFNalpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, interferon receptor 1, interferon-alpha/beta receptor alpha chain, interferon-beta receptor 1, Type I interferon receptor 1
Uniprot ID
Q8WTZ2
Mouse ortholog
Ifnar1 (15975)
interferon alpha/beta receptor 1 (Q80UJ3)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Avonex – Biogen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 44,003 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
228,767 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use